78 related articles for article (PubMed ID: 1960868)
21. Enhancement of migration activity in cholesterol-poor endothelial cells by pre-treating with HMG-CoA reductase inhibitors.
Ma L; Morita I; Murota S
Biochem Biophys Res Commun; 1994 Sep; 203(2):1355-61. PubMed ID: 8093051
[TBL] [Abstract][Full Text] [Related]
22. Drugs inhibiting HMG-CoA reductase.
Endo A
Pharmacol Ther; 1985; 31(3):257-67. PubMed ID: 3843353
[No Abstract] [Full Text] [Related]
23. Biochemical aspect of HMG CoA reductase inhibitors.
Endo A; Hasumi K
Adv Enzyme Regul; 1989; 28():53-64. PubMed ID: 2696346
[TBL] [Abstract][Full Text] [Related]
24. Pharmacology of competitive inhibitors of HMG-CoA reductase.
Corsini A; Maggi FM; Catapano AL
Pharmacol Res; 1995 Jan; 31(1):9-27. PubMed ID: 7784310
[No Abstract] [Full Text] [Related]
25. Enhancement of membrane fluidity in cholesterol-poor endothelial cells pre-treated with simvastatin.
Morita I; Sato I; Ma L; Murota S
Endothelium; 1997; 5(2):107-13. PubMed ID: 9237044
[TBL] [Abstract][Full Text] [Related]
26. Inhibitors of cholesterol biosynthesis. 6. trans-6-[2-(2-N-heteroaryl-3,5-disubstituted- pyrazol-4-yl)ethyl/ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones.
Sliskovic DR; Blankley CJ; Krause BR; Newton RS; Picard JA; Roark WH; Roth BD; Sekerke C; Shaw MK; Stanfield RL
J Med Chem; 1992 May; 35(11):2095-103. PubMed ID: 1597859
[TBL] [Abstract][Full Text] [Related]
27. Does the HMG-CoA reductase inhibitor pravastatin influence nucleation of cholesterol crystals in supersaturated model bile?
Smit JW; Van Erpecum KJ; Gadella MM; Van de Heyning BJ; Van Berge-Henegouwen GP
Eur J Gastroenterol Hepatol; 1996 Mar; 8(3):197-200. PubMed ID: 8724016
[TBL] [Abstract][Full Text] [Related]
28. The discovery and development of HMG-CoA reductase inhibitors.
Endo A
J Lipid Res; 1992 Nov; 33(11):1569-82. PubMed ID: 1464741
[No Abstract] [Full Text] [Related]
29. Lyso-PAF analogues and lysophosphatidylcholines from the marine sponge Spirastrella abata as inhibitors of cholesterol biosynthesis.
Shin BA; Kim YR; Lee IS; Sung CK; Hong J; Sim CJ; Im KS; Jung JH
J Nat Prod; 1999 Nov; 62(11):1554-7. PubMed ID: 10579872
[TBL] [Abstract][Full Text] [Related]
30. HMG-CoA reductase inhibitors and sleep.
Spielberg SP; Tobert JA
Clin Pharmacol Ther; 1992 Jul; 52(1):109-11. PubMed ID: 1623688
[No Abstract] [Full Text] [Related]
31. Simvastatin but not pravastatin has a direct inhibitory effect on rat and human myocyte proliferation.
Corsini A; Raiteri M; Soma MR; Gabbiani G; Paoletti R
Clin Biochem; 1992 Oct; 25(5):399-400. PubMed ID: 1490305
[No Abstract] [Full Text] [Related]
32. Lowering plasma cholesterol by raising ldl receptors. 1981.
Brown MS; Goldstein JL
Atheroscler Suppl; 2004 Oct; 5(3):57-9. PubMed ID: 15531276
[No Abstract] [Full Text] [Related]
33. Dihydromevinolin, a potent hypocholesterolemic metabolite produced by Aspergillus terreus.
Albers-Schönberg G; Joshua H; Lopez MB; Hensens OD; Springer JP; Chen J; Ostrove S; Hoffman CH; Alberts AW; Patchett AA
J Antibiot (Tokyo); 1981 May; 34(5):507-12. PubMed ID: 7275832
[TBL] [Abstract][Full Text] [Related]
34. Inhibitors of cholesterol biosynthesis. 1. 3,5-Dihydroxy-7-(N-imidazolyl)-6-heptenoates and -heptanoates, a novel series of HMG-CoA reductase inhibitors.
Chan C; Bailey EJ; Hartley CD; Hayman DF; Hutson JL; Inglis GG; Jones PS; Keeling SE; Kirk BE; Lamont RB
J Med Chem; 1993 Nov; 36(23):3646-57. PubMed ID: 8246233
[TBL] [Abstract][Full Text] [Related]
35. Ubiquinone does not rescue acute myeloid leukemia cells from growth inhibition by statins.
Burke LP; Lewis LD; Perez RP
Leukemia; 2003 Jan; 17(1):267-8. PubMed ID: 12529692
[No Abstract] [Full Text] [Related]
36. Molecular effects of HMG-CoA reductase inhibitors on smooth muscle cell proliferation.
Skaletz-Rorowski A; Eschert H; Pawlus E; Breithardt G
J Am Coll Cardiol; 2001 Jan; 37(1):337-8. PubMed ID: 11153768
[No Abstract] [Full Text] [Related]
37. Molecular approaches for production of pravastatin, a HMG-CoA reductase inhibitor: transcriptional regulation of the cytochrome p450sca gene from Streptomyces carbophilus by ML-236B sodium salt and phenobarbital.
Watanabe I; Serizawa N
Gene; 1998 Mar; 210(1):109-16. PubMed ID: 9524240
[TBL] [Abstract][Full Text] [Related]
38. Phosphorus-containing inhibitors of HMG-CoA reductase. 2. Synthesis and biological activities of a series of substituted pyridines containing a hydroxyphosphinyl moiety.
Robl JA; Duncan LA; Pluscec J; Karanewsky DS; Gordon EM; Ciosek CP; Rich LC; Dehmel VC; Slusarchyk DA; Harrity TW
J Med Chem; 1991 Sep; 34(9):2804-15. PubMed ID: 1895299
[TBL] [Abstract][Full Text] [Related]
39. Statins: in the beginning.
Lyons KS; Harbinson M
J R Coll Physicians Edinb; 2009 Dec; 39(4):362-4. PubMed ID: 20509462
[TBL] [Abstract][Full Text] [Related]
40. HMG-CoA reductase inhibitors and bile lithogenicity: cholesterol supersaturation or nucleation defect?
Ahmed HA; Jazrawi RP; Northfield TC
Eur J Gastroenterol Hepatol; 1996 Mar; 8(3):195-6. PubMed ID: 8724015
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
